abstract |
At least one compound from the angiogenesis inhibitor group of general formula (I) as compound A and at least one compound from the histone deacetylase inhibitor (HDAC) group of general formula (II) as compound B Pharmaceutical combinations comprising and their use for the treatment of different diseases resulting from permanent angiogenesis are described. |